129 related articles for article (PubMed ID: 16882082)
21. [Endometrioid adenocarcinoma of the prostate: a case report].
Tsutahara K; Fukuhara S; Mori N; Hara T; Yamaguchi S; Adachi S; Fujisue K
Hinyokika Kiyo; 2004 Sep; 50(9):649-52. PubMed ID: 15518134
[TBL] [Abstract][Full Text] [Related]
22. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
[TBL] [Abstract][Full Text] [Related]
23. Prostate adenocarcinoma manifesting as generalized lymphadenopathy.
Moura FM; Garcia LT; Castro LP; Ferrari TC
Urol Oncol; 2006; 24(3):216-9. PubMed ID: 16678051
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
25. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients.
Guichard G; Larré S; Gallina A; Lazar A; Faucon H; Chemama S; Allory Y; Patard JJ; Vordos D; Hoznek A; Yiou R; Salomon L; Abbou CC; de la Taille A
Eur Urol; 2007 Aug; 52(2):430-5. PubMed ID: 17412489
[TBL] [Abstract][Full Text] [Related]
26. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
Schröder FH; Roobol MJ
Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
[TBL] [Abstract][Full Text] [Related]
27. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
28. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer.
Kubota Y; Kamei S; Nakano M; Ehara H; Deguchi T; Tanaka O
Int J Urol; 2008 Apr; 15(4):322-6; discussion 327. PubMed ID: 18380820
[TBL] [Abstract][Full Text] [Related]
29. [The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men].
Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):16-8. PubMed ID: 18346372
[TBL] [Abstract][Full Text] [Related]
30. Impact of low prostate specific antigen on prostate cancer--a rare case report.
Schneider HB
Eur J Med Res; 2007 Jul; 12(7):311-3. PubMed ID: 17933704
[TBL] [Abstract][Full Text] [Related]
31. [A case of primary transitional cell carcinoma of the prostate].
Morikawa H; Cho M; Takada S; Fujimoto K; Uemura H; Ozono S; Hirao Y; Natsume O
Hinyokika Kiyo; 2003 Jun; 49(6):357-60. PubMed ID: 12894737
[TBL] [Abstract][Full Text] [Related]
32. Pure prostatic papillary adenocarcinoma with ductal features.
Yamashita S; Inaba Y; Soma F; Katayama Y
Hinyokika Kiyo; 2005 Mar; 51(3):207-9; discussion 210. PubMed ID: 15852679
[TBL] [Abstract][Full Text] [Related]
33. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
34. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
35. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
[TBL] [Abstract][Full Text] [Related]
36. Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors.
Park SC; Rim JS; Choi HY; Kim CS; Hong SJ; Kim WJ; Lee SE; Song JM; Yoon JH
Int J Urol; 2009 Aug; 16(8):670-5. PubMed ID: 19602007
[TBL] [Abstract][Full Text] [Related]
37. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
[TBL] [Abstract][Full Text] [Related]
39. [The assessment of pathological PSA values by the general practitioner--observation or intervention?].
Braun KP; Brookman-Amissah S; May M; Grassmel Y; Hoschke B; Braun V
Aktuelle Urol; 2009 May; 40(3):171-4. PubMed ID: 19479670
[TBL] [Abstract][Full Text] [Related]
40. [Significance of re-measurement of prostate specific antigen before prostate biopsy].
Saito T; Kitamura Y; Komatsubara S
Hinyokika Kiyo; 2006 Oct; 52(10):773-6. PubMed ID: 17131865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]